Abstract: Objective To observe the efficacy and safety of sofosbuvir / daclatasvir with ribavirin in the treatment of hepatitis C cirrhosis. Methods From May 2016 to May 2017 in our hospital, there were 129 patients with hepatitis C cirrhosis receiving 12-week sofosbuvir / daclatasvir with ribavirin therapy. Patients were followed up for 12 weeks after antiviral treatment, and sustained virologic response at week 12 post-treatment (SVR12), biochemical response, improvement of hepatic fibrosis and adverse reactions during treatment were observed. Results HCV RNA of the 129 patients was (5.9±1.33) lgIU/mL at baseline and (1.67±1.24) lgIU/mL after 2-week treatment. Among the patients, HCV RNA was undetectable in 75.78% patients after 2-week treatment and in 93.44% patients after 12-week treatment. FibroScan measurement of the patients was (17.57±9.86) at baseline and decreased to (8.32±1.47) at week 12 (t=15.852, P=0.000). Serum levels of total bilirubin (TBil), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were significantly decreased at week 2 compared to those at baseline, respectively (t=2.408, P=0.017; t=11.054, P=0.000; t=12.227, P=0.000). Besides, biochemical response reached 100%. Multivariate regression analysis of 6 patients without SVR12 showed that retreatment was an independent predictor. No serious adverse reactions occurred with fatigue and headache being the main adverse reactions. Conclusion The patients with hepatitis C cirrhosis who received sofosbuvir / daclatasvir with ribavirin therapy achieved very high SVR12 rate, high biochemical response rate and significant improvement of liver fibrosis with good safety.

Key words: Hepatitis C cirrhosis, Antiviral drugs, Treatment